^
    2d
    PHOX: Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=99, Recruiting, Mayo Clinic | Trial completion date: May 2031 --> May 2027 | Trial primary completion date: May 2031 --> May 2027
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • docetaxel • oxaliplatin • leucovorin calcium • fluorouracil topical
    8d
    ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Providence Health & Services | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    CRP (C-reactive protein)
    |
    capecitabine • galunisertib (LY2157299) • fluorouracil topical
    9d
    Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer (clinicaltrials.gov)
    P1, N=39, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    RAS wild-type
    |
    Verzenio (abemaciclib) • fluorouracil topical
    13d
    Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study (clinicaltrials.gov)
    P3, N=486, Recruiting, NRG Oncology | Initiation date: May 2026 --> Oct 2025
    Trial initiation date
    |
    cisplatin • gemcitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical
    19d
    Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • capecitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    20d
    EAY191-A6: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    MAPK1 (Mitogen-activated protein kinase 1)
    |
    BRAF V600E • BRAF V600
    |
    Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    1m
    NRG-HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA (clinicaltrials.gov)
    P2/3, N=685, Active, not recruiting, NRG Oncology | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial primary completion date
    |
    cisplatin • gemcitabine • paclitaxel • fluorouracil topical
    1m
    Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Mayo Clinic
    New P1/2 trial
    |
    capecitabine • fluorouracil topical
    2ms
    Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (clinicaltrials.gov)
    P1/2, N=15, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • fluorouracil topical • Novaferon (recombinant anti-tumor and anti-virus protein)
    2ms
    Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P3, N=290, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • fluorouracil topical
    2ms
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Chicago | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    2ms
    PHOX: Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=99, Recruiting, Mayo Clinic | Trial completion date: Nov 2026 --> May 2031 | Trial primary completion date: May 2026 --> May 2031
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • docetaxel • oxaliplatin • leucovorin calcium • fluorouracil topical